T1	Participants 77 132	hyperphosphatemic patients with end-stage renal disease
T2	Participants 193 240	patients receiving long-term dialysis treatment
T3	Participants 749 786	male and female hemodialysis patients
T4	Participants 1379 1383	n=73
T5	Participants 1631 1635	n=30
T6	Participants 1707 1711	n=31
T7	Participants 2300 2326	Chinese patients with ESRD
